9-27-04

IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENGLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON SELF. 2 4 2004 AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS, PQ BOX 1450, ALEXANDRIA, VA 22313-1450

Them Arash

Élaine C. Stracker

SEP 2 4 2004

PATENT

Attorney's Docket No.: 00025.04CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/766,647

Filed:

1/27/2004

Title

DELIVERY OF ANALGESICS THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

SEP.	7	4	2004

Date: _____

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/766,647 **Application Number TRANSMITTAL** 1/27/2004 Filing Date **FORM** Joshua D. Rabinowitz First Named Inventor (to be used for all correspondence after initial filing) Art Unit Not yet known **Examiner Name** To be assigned Attomey Docket Number 00025.04CON Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer identify below): Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Info. Discl. Statement (2 pp.) Incomplete Application Form 1449 (3 copies , 8 pages each) Copy of references / 75 Return postcard Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm **Customer Number 37485** ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Elaine C Stracker, Ph.D., J.D. Telephone (650)-687-3905 Individual name Signature rich

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name

Elaine C. Stracker

Signature

Date

SEP. 24, 2004

SEP. 2 4 2004

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1 of 8

Not Yet Known

Form PGO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00025.04CON		Application Number: 10/766,647
Applicant:	Joshua D. RABI	NOWITZ et al.

Group Art Unit:

U.S. PATENT DOCUMENTS

Filing Date: 1/27/2004

Examiner Initials	Ref. No.	Date	Document No.	Name	Clas s	Subclass	Filing Date If Appropriate
	1.	01/05/1965	3,164,600	Janssen et al.			
	2.	03/18/1969	3,433,791	Bentley et al.			
	3.	02/02/1971	3,560,607	Hartley et al.			
	4.	05/27/1980	Re. 30,285	Babington			
.	5.	01/23/1990	4,895,719	Radhakrishnun et al.		•	
	6.	09/17/1991	5,049,389	Radhakrishnun			
	7.	02/14/1995	5,388,574	Ingebrethsen			
•	8.	08/13/1996	5,544,646	Lloyd et al.		•	• . •
	9.	12/09/1997	5,694,919	Rubsamen et al.			
	10.	03/10/1998	5,724,957	Rubsamen et al.		-	
•	11.	04/07/1998	5,735,263	Rubsamen et al.			
	12.	04/14/1998	5,738,865	Baichwal et al.			
•	13.	06/02/1998	5,758,637	Ivri et al.	·	"'	
	14.	06/29/1999	5,915,378	Lloyd et al.			
	15.	08/10/1999	5,934,272	Lloyd et al.			
	16.	09/28/1999	5,957,124	Lloyd et al.			
	17.	10/05/1999	5,960,792	Lloyd et al.			
	18.	11/30/1999	5,993,805	Sutton et al.			
	19.	03/28/2000	6,041,777	Faithfull et al.			
	20.	04/18/2000	6,051,566	Bianco			
	21.	08/01/2000	6,095,134	Sievers et al.			
	22.	08/01/2000	6,095,153	Kessler et al.			i
	23.	08/15/2000	6,102,036	Slutsky et al.			
	24.	10/17/2000	6,133,327	Kimura et al.			
	25.	06/05/2001	6,241,969	Saidi et al.			
	26.	07/03/2001	6,255,334	Sands			
	27.	10/23/2001	6,306,431	Zhang et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 2 of 8

	Form PTO-1449		Docket Number: 00025.04CON Application Number: 10/766,647		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Joshua D. RABINOWITZ et al.			
	(Use several sheets if n	ecessary)	Filing Date: 1/27/2004	Group Art Unit:	Not Yet Known
					
28	. 04/23/2002	6,376,550	Raber et al.		
29	. 01/14/2003	6,506,762	Horvath et al.		
30	. 02/04/2003	6,514,482	Bartus et al.		
31	. 07/15/2003	6,591,839	Meyer et al.		
32	. 09/06/2001	US 2001/0020147	Staniforth et al.		
33	. 03/28/2002	US 2002/0037828	Wilson et al.		
34	. 05/16/2002	US 2002/0058009	Bartus et al.		
35	. 07/04/2002	US 2002/0086852	Cantor		
36	. 08/22/2002	US 2002/0112723	Schuster et al.		Ī
37	11/28/2002	US 2002/0176841	Barker et al.		
. 38	. 01/02/2003	US 2003/0004142	Prior et al.		
. 39	02/13/2003	US 2003/0032638	Kim et al.		
DDI	ATTENDATIONS A 1	VOLEGIE AD DELE		PENTE DOCEDA	ENTEC
REL 40	· · · · · · · · · · · · · · · · · · ·	MOLECULAR DELI 10/633,876	VERY CORPORATION PATHALE et al.	TENT DOCUM	ENTS
. 1	. 08/04/2003	T		TENT DOCUM	ENTS
. 40	. 08/04/2003 . 08/04/2003	10/633,876	Hale et al.	TENT DOCUM	ENTS
40	. 08/04/2003 . 08/04/2003 . 12/30/2003	10/633,876 10/633,877	Hale et al. Hale et al.	TENT DOCUM	ENTS
40 41 42	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003	10/633,876 10/633,877 10/749,537	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004	10/633,876 10/633,877 10/749,537 10/749,539	Hale et al. Hale et al. Rabinowitz et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149	Hale et al. Hale et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44 45	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,279	Hale et al. Hale et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44 45 46	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,279 10/766,566	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
. 40 41 . 42 . 43 . 44 . 45 . 46 . 47 . 48 . 49	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/767,115	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44 45 46 47 48	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44 45 46 47 48 49 50	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004 . 01/29/2004 . 01/29/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,566 10/766,574 10/766,634 10/767,115 10/768,205 10/768,220	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
. 40 41 . 42 . 43 . 44 . 45 . 46 . 47 . 48 . 49 . 50 . 51 . 52	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/767,115 10/768,205 10/768,220 10/768,281	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44 45 46 47 48 49 50 51 52 53	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,579 10/766,574 10/766,634 10/767,115 10/768,205 10/768,220 10/768,281 10/768,293	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
. 40 41 . 42 43 44 45 46 47 48 49 50 51	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,566 10/766,574 10/766,634 10/767,115 10/768,205 10/768,205 10/768,220 10/768,281 10/768,293 10/769,046	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS
40 41 42 43 44 45 46 47 48 49 50 51 52 53	. 08/04/2003 . 08/04/2003 . 12/30/2003 . 12/30/2003 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/27/2004 . 01/28/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004 . 01/29/2004	10/633,876 10/633,877 10/749,537 10/749,539 10/766,149 10/766,579 10/766,574 10/766,634 10/767,115 10/768,205 10/768,220 10/768,281 10/768,293	Hale et al. Hale et al. Rabinowitz et al.	TENT DOCUM	ENTS

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 3 of 8

Form PTO-1449		Docket Number: 00025.04CON Application Number: 107/66,647					
INFO		TION DISCLO	SURE CITATION CATION	Applicant: Joshua D. RABINOWITZ		INOWITZ et al.	
		(Use several sheets if	necessary)	Filing Date: 1/27/2004		Group Art Unit:	Not Yet Known
	56.	01/29/2004	10/769,157	Rabinowitz et al.	<u> </u>	. 	· · · · · · · · · · · · · · · · · · ·
	57.	01/29/2004	10/769,197	Rabinowitz et al.			
	58.	02/09/2004	10/775,583	Rabinowitz et al.			
	59.	02/09/2004	10/775,586	Rabinowitz et al.	\dashv		
	60.	03/03/2004	10/791,915	Hale et al.	+		
	61.	03/03/2004	10/792,001	Rabinowitz et al.			
	62.	03/03/2004	10/792,001	Hale et al.	+		•
	63.	03/03/2004	10/792,012	Rabinowitz et al.	+		
	64.	03/03/2004	10/792,013	Hale et al.	+		
	65.	03/03/2004	+ <u>-</u>	Hale et al.	-		
<u> </u>		03/03/2004	10/792,239	Rabinowitz et al.	+		
	66.		10/813,721				
-	67.	03/31/2004	10/813,722	Rabinowitz et al.	+		
	68.	03/31/2004	10/814,690	Rabinowitz et al.			
	69.	03/31/2004	10/814,998	Rabinowitz et al.			
-	70.	04/01/2004	10/815,527	Rabinowitz et al.	-		
	71.	04/01/2004	10/816,407	Rabinowitz et al.	_ -		
-	72.	04/01/2004	10/816,492	Rabinowitz et al.			
	73.	04/01/2004	10/816,567	Rabinowitz et al.	_		
	74.	08/04/2004	10/912,462	Hale et al.			
	75.	01/23/2003	US 2003/0015196	Hodges et al.			
·	76.	04/03/2003	US 2003/0062042	Wensley et al.			
	77.	11/13/2003	US 2003/0209240	Hale et al.			
	78.	01/02/2003	US 2003/0000518	Rabinowitz et al.			,
	79.	01/09/2003	US 2003/0005924	Rabinowitz et al.			
	80.	01/09/2003	US 2003/0005925	Hale et al.			
	81.	01/09/2003	US 2003/0007933	Rabinowitz et al.			
	82.	01/09/2003	US 2003/0007934	Rabinowitz et al.			
	83.	01/16/2003	US 2003/0012737	Rabinowitz et al.			
	84.	01/16/2003	US 2003/0012738	Rabinowitz et al.			
	85.	1/16/2003	US 2003/0012740	Rabinowitz et al.			
EXAMIN	NER:		,	DATE CONSIDERE	ED:		P
				ation conforms with MPEP 609. In next communication to applican		ine through the cita	tion if not in

PTO/SB/ 08 (2-92)

Sheet 4 of 8

Application Number: 10/766,647 Docket Number: 00025.04CON Form PTO-1449 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION Not Yet Known Filing Date: 1/27/2004 (Use several sheets if necessary) Group Art Unit: 01/23/2003 US 2003/0015189 Rabinowitz et al. 86. 01/23/2003 US 2003/0015190 Rabinowitz et al. 87. US 2003/0017114 Rabinowitz et al. 88. 01/23/2003 Rabinowitz et al. 89. 01/23/2003 US 2003/0017115 01/23/2003 US 2003/0017116 Rabinowitz et al. 90. 91. 01/23/2003 US 2003/0017117 Rabinowitz et al. Rabinowitz et al. 92. 01/23/2003 US 2003/0017118 01/23/2003 US 2003/0017119 Rabinowitz et al. 93. Rabinowitz et al. 94. 01/23/2003 US 2003/0017120 95. Rabinowitz et al. 1/30/2003 US 2003/0021753 01/30/2003 US 2003/0021754 Rabinowitz et al. 96. 01/30/2003 US 2003/0021755 Hale et al. 97. 98. 02/20/2003 US 2003/0035776 Hodges et al. 99. 05/15/2003 US 2003/0091511 Rabinowitz et al. US 2004/010148 Hale et al. 100. 05/27/2004 Rabinowitz 101. 07/31/2003 US 2003/0138382 Rabinowitz et al. US 2003/0206869 102. 11/06/2003 Rabinowitz et al. 103. 01/15/2004 US 2004/0009128 05/20/2004 US 2004/0096402 Hodges et al. 104. 05/27/2004 US 2004/0099269 Hale et al. 105. US 2004/0105818 Hale et al. 106. 06/03/2004 107. 06/03/2004 US 2004/0105819 Hale et al. US 2004/0126326 07/01/2004 Rabinowitz et al. 108. 109. 07/01/2004 US 2004/0126327 Rabinowitz et al. US 2004/0126328 Rabinowitz et al. 110. 07/01/2004 07/01/2004 US 2004/0126329 Rabinowitz et al. 111. US 2004/0127481 Rabinowitz et al. 112. 07/01/2004 07/01/2004 US 2004/0127490 Rabinowitz et al. 113. US 2004/0156788 Rabinowitz et al. 114. 08/12/2004 US 2004/0156789 Rabinowitz et al. 115. 08/12/2004 DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

PTO/SB/08 (2-92) Sheet 5 of 8 Application Number: 10/766,647 Form PTO-1449 Docket Number: 00025.04CON Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION (Use several sheets if necessary) Filing Date: 1/27/2004 Group Art Unit: Not Yet Known 8/12/2004 US 2004/0156790 Rabinowitz et al. 116. 08/12/2004 US 2004/0156791 Rabinowitz et al. 117. FOREIGN PATENT DOCUMENTS Subclass Translation Examiner Ref. Date Document No. Country Class YES NO **Initials** No. 118. 03/14/1990 EP 0 358 114 Europe 02/06/2000 EP 1 177 793 119. Europe 120. 07/03/2001 EP 1 080 720 Europe 121. 08/29/2001 EP 0 606 486 Europe 06/13/1991 WO 91/07947 **WIPO** 122. 04/16/1992 WO 92/05781 WIPO 123. 124. 04/11/1996 WO 96/09846 **WIPO** 125. 05/09/1996 WO 96/13161 **WIPO** 126. 05/09/1996 WO 96/13290 **WIPO** 05/09/1996 WO 96/13291 **WIPO** 127. **WIPO** 128. 05/09/1996 WO 96/13292 129. 10/03/1996 WO 96/30068 WIPO 05/22/1997 WO 97/17948 WIPO 130. 08/07/1997 WO 97/27804 **WIPO** 131. 05/28/1998 WO 98/22170 **WIPO** 132. 07/23/1998 WO 98/31346 133. **WIPO** 08/27/1998 **WIPO** 134. WO 98/36651 04/08/1999 WO 99/16419 135. WIPO

EXAMINER:

136.

137.

138.

12/16/1999

01/06/2000

01/06/2000

WO 99/64094

WO 00/00176

WO 00/00215

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

WIPO

WIPO

WIPO

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Joshua D. RABINOWITZ et al.				
						(Use several sheets if necessary)
	<u></u>					
	139.	05/18/2000	WO 00/27363	WIPO		
	140.	05/25/2000	WO 00/29053	WIPO		
	141.	09/17/2000	WO 00/47203	WIPO		
	142.	11/02/2000	WO 00/64940	WIPO		
··	143.	11/09/2000	WO 00/66084	WIPO		
	144.	11/09/2000	WO 00/66206	WIPO		
	145.	12/07/2000	WO 00/72827	WIPO		
	146.	12/21/2000	WO 00/76673	WIPO		
	147.	01/25/2001	WO 01/05459	WIPO		
,	148.	03/01/2001	WO 01/13957	WIPO		·
	149.	03/15/2001	WO 01/17568	WIPO		
· 	150.	03/28/2002	WO 02/24158	WIPO		
Examiner Initials	Ref. No.	Title		,		
initials	No.			Controlled Analgesia: A New	Concept of Postope	erative Pain
	1.00		al Surg. 195(6):700-70		1	1 1 -1-1-1-1
	152.		et al. (1990), "Cocaine hopharmacology (Berl	-base smoking in rhesus mon). 102:443-450.	ikeys: reinforcing an	d physiological
• •	153.		Byron, P. (1986). "Degrank. 166:13-24.	pendence of Pulmonary Abso	orption Kinetics on A	Aerosol Particle
	154.			l Dispersion in Human Lung lus Tests," <i>American Physiol</i>		
	155.	Davies, C.N. 6 32(5):591-600		eathing of Half-Micron Aeros	ols," Journal of App	lied Physiology
	156.			per 2000). "Pharmacokinetics lthy Volunteers," Anesthesion		
	157.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.			c Press: San	
		1 = 1-8-1 - 1 - 1 - 1				
EXAMI	NER.			DATE CONSIDERED);	
		ial if citation consid	dered, whether or not the city	ation conforms with MPEP 609. Dr	<u> </u>	ation if not in
				n next communication to applicant.		
PTO/SB/ 08 ((2-92)			Patent and Trademark Off	ice; U.S. DEPARTMEN	T OF COMMERCE

Form PTO-1449		Docket Number: 00025.04CON Application Number: 10/766,647			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant: Joshua D. RABINOWITZ et al.			
		Filing Date: 1/27/2004	Group Art Unit: Not Yet Known		
158.	Gonda,I. (1991). "Particle Deposition Scientific Foundations. Crystal R.G. a 2294.	in the Human Respiratory Tract and West, J.B. (eds.), Raven Pub	t," Chapter 176, <u>The Lung:</u> lishers, New York. pp. 2289-		
159.	Hatsukami D, et al. (May 1990) "A m humans." Pharmacology Biochemistry		ses of smoked cocaine-base to		
160.					
161.					
162.	Hurt, R.D., MD and Robertson, C.R., Industry's Secrets About Nicotine: The	Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," JAMA 280(13):1173-1181.			
163.		Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.			
164.	Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," Journal of Analytical Toxicology 13:158-162.				
165.	Mattox, A.J. and Carroll, M.E., (1996 Psychopharmacology, 125:195-201.	Mattox, A.J. and Carroll, M.E., (1996). "Smoked heroin self-administration in rhesus monkeys," <i>Psychopharmacology</i> , 125:195-201.			
166.	Meng, Y. et al. "Inhalation Studies W 173:201-224.	Meng, Y. et al. "Inhalation Studies With Drugs of Abuse, " NIDA Research Monograph, (1997)			
167.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," Drug and Alcoh		e and other stimulants via		
168.	Office Action mailed 8/13/2003 for UBENZODIAZEPINES THROUGH A		05/21/2002 "DELIVERY OF		
169.	Pankow, J.F. et al. (1997). "Conversion Free-Base Form Through the Action of	on of Nicotine in Tobacco Smok of Gaseous Ammonia," <i>Envron</i> .	e to Its Volatile and Available Sci. Technol. 31:2428-2433.		
170.	Pankow, J. (March 2000). ACS Confe pp. 1-8.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke.			
171.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.				
172.	Sekine, H. and Nakahara, Y. (1987). 'Inhalation Efficiency and Pyrolysis Pt 32(5):1271-1280.				
173.	Vapotronics, Inc. (1998) located at http://www.vapotronics.com.au/banner.htm , 11 pages, (visited June 5, 2000).				
EXAMINER:		DATE CONSIDERED:			
	nitial if citation considered, whether or not the citat		line through the citation if not in		

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Docket Number: 00025.04CON Application Number: 10/766,647 Applicant: Joshua D. RABINOWITZ et al.		
	(Us	se several sheets if necessary)	Filing Date: 1/27/2004	Group Art Unit: Not Yet Known	
	124	Ward M.E. MD. and Marshard Marshard	07) "Mambin Pharmacalination	on often Dulmonessy	
	174.	Ward, M.E. MD, et al. (December 1999) Administration from a Novel Aerosol 62(6):596-609.	l Delivery System," Clinical Pho	armacology & Therapeutics	
	175.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and D Biochemistry & Behavior. 55(2):237-	emonstration of Their Biologica	f Cocaine Base and Its al Activity." <i>Pharmacology</i>	
			·		
				•	
		•	·		
·	·				
				·	
FYANG	NER:	·	DATE CONSIDERED:		

conformance and not considered. Include a copy of this form with next communication to applicant.